Assessing the Performance of a 60-GHz Dense Small-Cell Network Deployment from Ray-Based Simulations

Future dense small-cell networks are one key 5G candidates to offer outdoor high access data rates, especially in millimeter wave (mmWave) frequency bands. At those frequencies, the free space propagation loss and shadowing (from buildings, vegetation or any kind of obstacles) are far stronger than in the traditional radio cellular spectrum. Therefore, the cell range is expected to be limited to 50 - 100 meters, and directive high gain antennas are required at least for the base stations. This paper investigates the kind of topology that is required to serve a suburban area with a small-cell network operating at 60 GHz and equipped with beam-steering antennas. A real environment is considered to introduce practical deployment and propagation constraints. The analysis relies on Monte-Carlo system simulations with non-full buffer, and ray-based predictions. The ray-tracing techniques are today identified as a relevant solution to capture the main channel properties impacting the beam-steering performance (angular dispersion, inter-link correlation); and the one involved in the present study was specifically enhanced to deal with detailed vegetation modeling. In addition to the user outage, the paper evaluates the evolution of the inter-cell interference along with the user density, and investigates the network behavior in case of local strong obstructions.Comment: IEEE 21st International Workshop on Computer Aided Modelling and Design of Communication Links and Networks (CAMAD), October 201

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: Patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

BACKGROUND: In the phase III CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; ≥10 mutations/megabase). AIM: To evaluate patient-reported outcomes (PROs) in this population. METHODS: Disease-related symptoms and general health status were assessed using the validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) and EQ-5D, respectively. LCSS average symptom burden index (ASBI) and three-item global index (3-IGI) and EQ-5D visual analogue scale (VAS) and utility index (UI) scores and changes from baseline were analysed descriptively. Longitudinal changes were assessed by mixed-effect model repeated measures (MMRMs) and time to first deterioration/improvement analyses. RESULTS: In the high TMB population, PRO questionnaire completion rates were ∼90% at baseline and \u3e80% for most on-treatment assessments. During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) or improved following induction (EQ-5D VAS). MMRM-assessed changes in symptom burden were improved with nivolumab + ipilimumab versus chemotherapy. Symptom deterioration by week 12 was lower with nivolumab + ipilimumab versus chemotherapy (22.3% versus 35.0%; absolute risk reduction: 12.7% [95% confidence interval 2.4-22.5]), irrespective of discontinuation. Time to first deterioration was delayed with nivolumab + ipilimumab versus chemotherapy across LCSS and EQ-5D summary measures. CONCLUSION: First-line nivolumab + ipilimumab demonstrated early, sustained improvements in PROs versus chemotherapy in patients with advanced NSCLC and high TMB. CLINICAL TRIAL REGISTRATION: NCT02477826

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: Patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

BACKGROUND: In the phase III CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; ≥10 mutations/megabase). AIM: To evaluate patient-reported outcomes (PROs) in this population. METHODS: Disease-related symptoms and general health status were assessed using the validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) and EQ-5D, respectively. LCSS average symptom burden index (ASBI) and three-item global index (3-IGI) and EQ-5D visual analogue scale (VAS) and utility index (UI) scores and changes from baseline were analysed descriptively. Longitudinal changes were assessed by mixed-effect model repeated measures (MMRMs) and time to first deterioration/improvement analyses. RESULTS: In the high TMB population, PRO questionnaire completion rates were ∼90% at baseline and \u3e80% for most on-treatment assessments. During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) or improved following induction (EQ-5D VAS). MMRM-assessed changes in symptom burden were improved with nivolumab + ipilimumab versus chemotherapy. Symptom deterioration by week 12 was lower with nivolumab + ipilimumab versus chemotherapy (22.3% versus 35.0%; absolute risk reduction: 12.7% [95% confidence interval 2.4-22.5]), irrespective of discontinuation. Time to first deterioration was delayed with nivolumab + ipilimumab versus chemotherapy across LCSS and EQ-5D summary measures. CONCLUSION: First-line nivolumab + ipilimumab demonstrated early, sustained improvements in PROs versus chemotherapy in patients with advanced NSCLC and high TMB. CLINICAL TRIAL REGISTRATION: NCT02477826

Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/ French-Language Oncology Group (GOLF)

Systematic molecular profiling and targeted therapy (TKI) have changed the face of Non-Small Cell Lung Cancer (NSCLC) treatment. However, there are no specific recommendations to address the prescription of TKI for older patients. A multidisciplinary task force from the French Society of Geriatric Oncology (SoFOG) and the French Society of Pulmonology/Oncology Group (SPLF/GOLF) conducted a systematic review from May 2010 to May 2021. Protocol registered in Prospero under number CRD42021224103. Three key questions were selected for older patients with NSCLC: (1) to whom TKI can be proposed, (2) for whom monotherapy should be favored, and (3) to whom a combination of TKI can be proposed. Among the 534 references isolated, 52 were included for the guidelines. The expert panel analysis concluded: (1) osimertinib 80 mg/day is recommended as a first-line treatment for older patients with the EGFR mutation; (2) full-dose first generation TKI, such as erlotinib or gefitinib, is feasible; (3) ALK and ROS1 rearrangement studies including older patients were too scarce to conclude on any definitive recommendations; and (4) given the actual data, TKI should be prescribed as monotherapy. Malnutrition, functional decline, and the number of comorbidities should be assessed primarily before TKI initiation. © 2022 by the authors. Licensee MDPI, Basel, Switzerland

A Defined Terminal Region of the E. coli Chromosome Shows Late Segregation and High FtsK Activity

Background: The FtsK DNA-translocase controls the last steps of chromosome segregation in E. coli. It translocates sister chromosomes using the KOPS DNA motifs to orient its activity, and controls the resolution of dimeric forms of sister chromosomes by XerCD-mediated recombination at the dif site and their decatenation by TopoIV. Methodology: We have used XerCD/dif recombination as a genetic trap to probe the interaction of FtsK with loci located in different regions of the chromosome. This assay revealed that the activity of FtsK is restricted to a,400 kb terminal region of the chromosome around the natural position of the dif site. Preferential interaction with this region required the tethering of FtsK to the division septum via its N-terminal domain as well as its translocation activity. However, the KOPSrecognition activity of FtsK was not required. Displacement of replication termination outside the FtsK high activity region had no effect on FtsK activity and deletion of a part of this region was not compensated by its extension to neighbouring regions. By observing the fate of fluorescent-tagged loci of the ter region, we found that segregation of the FtsK high activity region is delayed compared to that of its adjacent regions. Significance: Our results show that a restricted terminal region of the chromosome is specifically dedicated to the last step

Autoantibodies against type I IFNs in patients with critical influenza pneumonia

In an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine. Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-alpha 2 alone (five patients) or with IFN-omega (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-alpha 2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-omega. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-alpha 2 and IFN-omega (OR = 11.7, P = 1.3 x 10(-5)), especially those <70 yr old (OR = 139.9, P = 3.1 x 10(-10)). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for similar to 5% of cases of life-threatening influenza pneumonia in patients <70 yr old

Analyse clinique, immunohistochimique et génétique de 50 tumeurs épithéliales thymiques prises en charge au CHU de Rennes de 2000 à 2011

Rationnel. Les tumeurs éptihéliales thymiques (TET) font l'objet d'un intérêt croissant. Patients et méthodes. Les données cliniques des sujets atteints de TET de 2000 à 2011 au CHU de Rennes ont été étudiées. L'expression des protéines ERCC1, VEGF, VEGFR2, PDGFR et HER2 a été évaluée par immunohistochimie. Des mutations ont été recherchées sur les gènes PIK3CA NRAS, BRAF, HER2. Un réarrangement de ALK a été recherché par FISH. Résultats. Les caractéristiques cliniques des 50 TET retrouvées étaient comparables aux séries publiées et leur prise en charge conforme aux recommandations. Une expression supérieure du VEGF et du VEGF1 était observée dans les carcinomes thymiques. Une mutation de NRAS étaité identifiée dans un thymome B1. L'analyse de ALK ne retrouvait pas de réarrangement. La survie était supérieure en cas de myasthénie et de chirurgie. Conclusion. Si l'analyse de l'angiogenèse est une piste intéressante, le gène ALK ne semble pas impliqué dans la biologie des TET.RENNES1-BU Santé (352382103) / SudocSudocFranceF

Etude rétrospective portant sur des fistules artérioveineuses pulmonaires traitées par embolisation dans le cadre de la télangiectasie hémorragique héréditaire (à propos de douze cas)

CAEN-BU Médecine pharmacie (141182102) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Recherche de mutations EGFR et K-Ras chez les patients de cancer bronchique non à petites cellules suivis au CHU de Rennes (faisabilité en pratique courante et analyse des résultats)

RENNES1-BU Santé (352382103) / SudocSudocFranceF

OCTOMUT, étude observationnelle évaluant les modalités diagnostiques, thérapeutiques, de suivi et d'évolution des patients âgés de 80 ans et plus porteurs d'un cancer bronchique non à petites cellules avec mutation activatrice du gène de l'EGFR

Introduction: Nous présentons une étude rétrospective sur les patients de 80 ans et plus porteurs d'un CBNPC avec mutation activatrice de l'EGFR. Nous analysons les données épidémiologiques et l'utilisation des EGFR-TKI. Patients et méthode: Les plateformes de biologie moléculaire de Brest, Caen, Rennes et Nantes nous ont fournis la liste des patients de 80 ans et plus dont la recherche de mutation de l'EGFR était positive entre janvier 2010 et juin 2012. Nous avons contacté leurs médecins qui ont rempli des questionnaires les concernant. Résultats: Nous avons récupéré 44 dossiers. Il y a 73% de femmes, 73% de non-fumeurs, d'âge médian 84 ans, autonomes au domicile (93%). Ils sont porteurs d'adénocarcinomes (93%) métastatiques (80%). Les mutations retrouvées sont la délétion de l'exon 19 (52%) et les substitutions de l'exon 21 (48%). 34 patients ont bénéficié d'EGFR-TKI avec un taux de réponse globale de 90%. La SSI est de 12 mois et la SG est de 16 mois. 71% ont présenté des effets secondaires. Conclusion: Les patients de 80 ans porteurs d'un cancer muté EGFR peuvent bénéficier d'EGFR-TKI avecune bonne efficacité, au prix d'effets secondaires non négligeables.Introduction: We presented a retrospective study on patients aged 80 years or older with NSCLC harboring an activated mutation of EGFR. We analyzed epidemiologic, effect and tolerance of EFGR-TKI. Patients and methods: Listing of older patients was determined by biologic platforms of Rennes, Nantes, Brest and Caen. Theirs patricians were contacted to fill the form. Results: Between January 2010 and June 2012, 44 patients were enrolled. The median age was 84 years. 73% of patients were women, 73% were never smoked, 93% were self-ruling and 93% had adenocarcinoma. The disease control rate was 90%. The median progression-free survival was 12 months and the median overall survival was 16 months. The adverse events occurred at 71%. Conclusion: This study verified safety and efficacy of treatment with TKI-EGFR in elderly patients having NSCLC with EGFR mutation.RENNES1-BU Santé (352382103) / SudocSudocFranceF